A detailed history of Susquehanna International Group, LLP transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 79,915 shares of XERS stock, worth $233,351. This represents 0.0% of its overall portfolio holdings.

Number of Shares
79,915
Previous 32,246 147.83%
Holding current value
$233,351
Previous $72,000 215.28%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.06 - $2.96 $98,198 - $141,100
47,669 Added 147.83%
79,915 $227,000
Q2 2024

Aug 15, 2024

BUY
$1.7 - $2.45 $8,255 - $11,897
4,856 Added 17.73%
32,246 $72,000
Q1 2024

May 07, 2024

SELL
$2.04 - $3.22 $277,111 - $437,401
-135,839 Reduced 83.22%
27,390 $60,000
Q4 2023

Feb 14, 2024

BUY
$1.47 - $2.36 $83,787 - $134,515
56,998 Added 53.65%
163,229 $383,000
Q3 2023

Nov 14, 2023

SELL
$1.8 - $2.69 $31,393 - $46,916
-17,441 Reduced 14.1%
106,231 $197,000
Q2 2023

Aug 11, 2023

SELL
$1.82 - $2.98 $17,692 - $28,968
-9,721 Reduced 7.29%
123,672 $324,000
Q1 2023

May 16, 2023

BUY
$1.03 - $1.63 $71,918 - $113,813
69,824 Added 109.84%
133,393 $217,000
Q4 2022

Feb 14, 2023

SELL
$1.14 - $1.65 $36,728 - $53,159
-32,218 Reduced 33.64%
63,569 $84,000
Q3 2022

Nov 14, 2022

BUY
$1.37 - $1.93 $44,381 - $62,522
32,395 Added 51.1%
95,787 $149,000
Q2 2022

Aug 15, 2022

SELL
$1.48 - $2.64 $532,480 - $949,829
-359,784 Reduced 85.02%
63,392 $98,000
Q1 2022

May 16, 2022

SELL
$2.0 - $2.87 $822,720 - $1.18 Million
-411,360 Reduced 49.29%
423,176 $1.08 Million
Q4 2021

Feb 14, 2022

BUY
$1.8 - $2.93 $1.5 Million - $2.45 Million
834,536 New
834,536 $2.45 Million

Others Institutions Holding XERS

About Xeris Biopharma Holdings, Inc.


  • Ticker XERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,956,992
  • Market Cap $397M
  • Description
  • Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...
More about XERS
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.